$146.70 Million in Sales Expected for Dynavax Technologies Co. (NASDAQ:DVAX) This Quarter – MarketBeat

Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Brokerages expect Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) to report $146.70 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Dynavax Technologies’ earnings. The lowest sales estimate is $146.68 million and the highest is $146.72 million. Dynavax Technologies reported sales of $52.77 million in the same quarter last year, which suggests a positive year-over-year growth rate of 178%. The business is expected to announce its next earnings report on Monday, January 1st.
On average, analysts expect that Dynavax Technologies will report full year sales of $653.10 million for the current fiscal year, with estimates ranging from $649.50 million to $656.69 million. For the next year, analysts expect that the firm will report sales of $298.76 million, with estimates ranging from $136.40 million to $461.12 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX – Get Rating) last posted its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.02). The company had revenue of $113.99 million for the quarter, compared to analyst estimates of $117.76 million. Dynavax Technologies had a return on equity of 87.36% and a net margin of 23.12%. During the same period last year, the firm earned $0.01 EPS.
Whether you’re looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today’s futures markets!
Several equities research analysts have recently weighed in on DVAX shares. StockNews.com cut Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, May 12th. Zacks Investment Research lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, March 1st. Finally, TheStreet upgraded Dynavax Technologies from a “d+” rating to a “c” rating in a report on Wednesday, March 30th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Dynavax Technologies presently has a consensus rating of “Hold” and a consensus price target of $21.00.
NASDAQ:DVAX opened at $12.12 on Friday. The stock has a fifty day moving average price of $10.32 and a 200-day moving average price of $12.16. The company has a market cap of $1.53 billion, a price-to-earnings ratio of 22.04 and a beta of 1.41. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.85 and a current ratio of 2.02. Dynavax Technologies has a fifty-two week low of $7.26 and a fifty-two week high of $21.39.
In other Dynavax Technologies news, insider Justin Burgess sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 17th. The shares were sold at an average price of $10.00, for a total value of $60,000.00. Following the completion of the transaction, the insider now owns 3,854 shares of the company’s stock, valued at approximately $38,540. The transaction was disclosed in a filing with the SEC, which is available through this link. 9.31% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the stock. Advisors Asset Management Inc. raised its holdings in Dynavax Technologies by 498.0% in the 1st quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 1,967 shares in the last quarter. Quantbot Technologies LP grew its position in shares of Dynavax Technologies by 940.7% in the 1st quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 2,267 shares during the period. Signaturefd LLC grew its position in shares of Dynavax Technologies by 12,690.7% in the 1st quarter. Signaturefd LLC now owns 5,500 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 5,457 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in shares of Dynavax Technologies in the 3rd quarter worth about $163,000. Finally, Maverick Capital Ltd. purchased a new stake in shares of Dynavax Technologies in the 3rd quarter worth about $176,000. Institutional investors own 76.80% of the company’s stock.
About Dynavax Technologies (Get Rating)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Dynavax Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Dynavax Technologies wasn’t on the list.
While Dynavax Technologies currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here

Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
In this episode, Kate’s guest is Tyler Laundon, editor of the Cabot Small-Cap Confidential and grand slam advisory Cabot Early Opportunities newsletters. Tyler shares his analysis of the small-cap asset class, within the lens of the broader market. He also offers some stocks he’s eyeing right now as potential watch-list candidates.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.

source

Related Articles